Accumulating evidence indicates that monoclonal antibodies targeting programmed death-1 (PD-1) receptor and its ligand (PD-L1) have demonstrated clinical responses and survival improvement in the treatment of patients with advanced-stage cancers (4). Here, CD274 is linked to cancer.